|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable and accruals | ||||||||||||||||||||
| Loans payable | ||||||||||||||||||||
| Note payable | ||||||||||||||||||||
| Due to a related party | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Preferred stock, value | ||||||||||||||||||||
| Series A Preferred Stock | ||||||||||||||||||||
| Total preferred stock, value | ||||||||||||||||||||
| Common Stock, $0.0001 par value, 100,000,000 shares authorized; 53,528,001 and 53,528,001 shares issued and outstanding, respectively. | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Stockholders’ deficit | ||||||||||||||||||||
| Total Liabilities and Stockholders’ Deficit | ||||||||||||||||||||
Loading...
